Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 148 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3UWlEPTB;MD6wNFAxODNyMzFOwG0> NGLD[4dUSU6JRWK=
MONO-MAC-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV74fo9GUUN3ME2wMlAxPDF6IN88US=> MmfPV2FPT0WU
ALL-PO NGrBUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PRRWlEPTB;MD6wN|E5PCEQvF2= M37tbXNCVkeHUh?=
NKM-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEe0NVYh|ryP MVjTRW5ITVJ?
CGTH-W-1 NXrMcVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMkWwNlIh|ryP NFT5d|JUSU6JRWK=
BB65-RCC MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3uTWM2OD1yLkS3NFc{KM7:TR?= Mn\6V2FPT0WU
NOS-1 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;tTHRjUUN3ME2wMlU3OzZizszN NEG3XYJUSU6JRWK=
SH-4 NH7tVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PIbGlEPTB;MD62OVYyOyEQvF2= MUjTRW5ITVJ?
HOP-62 Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPRVHdKSzVyPUCuPFUxQDhizszN M1P5SnNCVkeHUh?=
HCC2998 NY\nUlJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\zTWM2OD1yLki4PFE5KM7:TR?= NILzOFNUSU6JRWK=
GDM-1 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvFZnBKSzVyPUCuPVA3QThizszN NEXjeVVUSU6JRWK=
KM12 M3KyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwMEKwPVgh|ryP MlrwV2FPT0WU
LB2518-MEL NVX4Rnh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMkC4NFkh|ryP NX7YVZByW0GQR1XS
NCI-H1436 NEf4N4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmxeZhKSzVyPUGuNlE3PzhizszN NWL0SmhiW0GQR1XS
EM-2 M1TNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LYUWlEPTB;MT6zOVU4QCEQvF2= M1\T[HNCVkeHUh?=
LAMA-84 M2fJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf2clc3UUN3ME2xMlM4PjR6IN88US=> NH2y[IlUSU6JRWK=
KG-1 NEPvTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTRTWM2OD1zLkS3PVM2KM7:TR?= M3exS3NCVkeHUh?=
A388 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmTWM2OD1zLkW5NVY2KM7:TR?= M4fwfXNCVkeHUh?=
no-10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ObZNKSzVyPUGuOlE4OjZizszN MVXTRW5ITVJ?
SF126 NVywe4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTzTWM2OD1zLk[zPFEzKM7:TR?= Mn7jV2FPT0WU
MEG-01 NHXGfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzaTWM2OD1zLkiwPVgh|ryP MYPTRW5ITVJ?
A3-KAW MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHFTWM2OD1zLki4OFIh|ryP MlzaV2FPT0WU
D-247MG M2jmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr2ZpZKSzVyPUKuNVQ1QCEQvF2= NYfuSHRMW0GQR1XS
OVCAR-4 NYXzdGhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\OWmU4UUN3ME2yMlIyOzl|IN88US=> NVzpZXpTW0GQR1XS
NCI-SNU-1 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHoTWM2OD1{LkOxOlIh|ryP NIXXT2ZUSU6JRWK=
NCI-H2171 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1{LkO5O|Y1KM7:TR?= MWTTRW5ITVJ?
SIG-M5 NEi0d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzNVY5KSzVyPUKuOFIzPDJizszN NWHFd2tSW0GQR1XS
BE-13 NFPUZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5VnpKSzVyPUKuOlk3ODlizszN NG\SRm9USU6JRWK=
K052 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwN{S2NVYh|ryP MoDaV2FPT0WU
L-540 NXnHW5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPVT|ZVUUN3ME2yMlc2Pzh7IN88US=> NWjPdnoyW0GQR1XS
KMOE-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLwc5ZKSzVyPUKuPFE{PSEQvF2= NXLYO3JNW0GQR1XS
MFH-ino M13xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDyc|U3UUN3ME2yMlkzOTh3IN88US=> NESwPWtUSU6JRWK=
HL-60 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTYWZlKSzVyPUOuNFYzQTlizszN NInkZYhUSU6JRWK=
HCC2218 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1voWWlEPTB;Mz6xNlAxOyEQvF2= NEe5[GNUSU6JRWK=
TE-5 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH6TWM2OD1|LkGzNVYzKM7:TR?= MYLTRW5ITVJ?
MZ1-PC M1HGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yZ3hnUUN3ME2zMlQ4PTB7IN88US=> MVTTRW5ITVJ?
MRK-nu-1 NVrhSZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTVTWM2OD1|Lk[xOFY5KM7:TR?= NVO2ZnlPW0GQR1XS
MZ7-mel MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTpTWM2OD1|Lk[2NFk6KM7:TR?= NX75UVZFW0GQR1XS
BC-1 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLJSIU1UUN3ME2zMlc1ODJizszN NH3W[ZFUSU6JRWK=
ST486 NVjpXos5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LEcWlEPTB;Mz64N|Y4OyEQvF2= MWLTRW5ITVJ?
KS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjpXlNKSzVyPUOuPFgyQThizszN NF2wOG5USU6JRWK=
SK-NEP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;ne3RiUUN3ME20MlE3QDF3IN88US=> NWXEclhlW0GQR1XS
BC-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRwMkOzPVEh|ryP Mn3QV2FPT0WU
NCI-H1581 NWjQfZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0[2lEPTB;ND6yPFc6QCEQvF2= NH7sVnFUSU6JRWK=
MHH-PREB-1 NFWxTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HZc2lEPTB;ND60NFQ5PCEQvF2= NGThPGRUSU6JRWK=
NOMO-1 M2C2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwNEi5NFUh|ryP M4rjNXNCVkeHUh?=
QIMR-WIL NHLvOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3THWGlEPTB;NT6wO|I6PCEQvF2= M1TWbnNCVkeHUh?=
SF539 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn3[pBKSzVyPUWuNVMzOjdizszN MlP3V2FPT0WU
TE-12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TKZ2lEPTB;NT6yOFkzQSEQvF2= NXzyTJR5W0GQR1XS
NCI-H510A M{f2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT1TWM2OD13LkSxOlg2KM7:TR?= MXvTRW5ITVJ?
JAR NGTGXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPicVh1UUN3ME21MlUxQDJ2IN88US=> MmLLV2FPT0WU
no-11 NHPRbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K0TmlEPTB;NT63N|U3QCEQvF2= NGP2ZlBUSU6JRWK=
BV-173 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Wxe2lEPTB;NT65OVY5OiEQvF2= MoTRV2FPT0WU
SR NXXlfVF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojXTWM2OD14LkCwOlc5KM7:TR?= NI\6U5dUSU6JRWK=
MOLT-16 NILXc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmzRnZMUUN3ME22MlI2OjZ4IN88US=> MYTTRW5ITVJ?
MZ2-MEL NHnrSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXlTWM2OD14LkOxPFM6KM7:TR?= M3zJXHNCVkeHUh?=
SW954 NXHhbYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD14LkS1PFY3KM7:TR?= M{PVWXNCVkeHUh?=
ML-2 M3Tvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GxfGlEPTB;Nj61Nlg1QSEQvF2= Mo\vV2FPT0WU
OCI-AML2 M3TFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXDTWM2OD14Lk[xNFYzKM7:TR?= M2TrbXNCVkeHUh?=
SIMA Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZT2lEPTB;Nz6wNFExOSEQvF2= M3ThV3NCVkeHUh?=
DOHH-2 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTdwMEW2O|Yh|ryP Mn\0V2FPT0WU
697 M2iycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC4TWM2OD15LkC1PVg6KM7:TR?= NXrFZ|IyW0GQR1XS
NB1 M2ftPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\zdHFXUUN3ME23MlQxPDB5IN88US=> Mkn2V2FPT0WU
D-392MG NGDrNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfDOW5KSzVyPUeuOlI3PjNizszN NGHMfWNUSU6JRWK=
ES8 NY\Bbph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjTWM2OD15Lke2OVA{KM7:TR?= MmfPV2FPT0WU
RPMI-8226 NH61eXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D1OWlEPTB;Nz64OFUyOSEQvF2= M4XpcHNCVkeHUh?=
IST-MEL1 NHztRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HBVGlEPTB;OD60NFAxOiEQvF2= NWHWfIdEW0GQR1XS
NB14 M3PrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDL[otKSzVyPUiuOlMyOzNizszN Mn3VV2FPT0WU
HD-MY-Z M2DHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1faXWlEPTB;OD62N|c1PiEQvF2= NYHsNG9EW0GQR1XS
TE-10 M1jZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjSS5RKSzVyPUiuO|Y{PTNizszN MnHTV2FPT0WU
LC-1F MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTlwMUC4N|Qh|ryP MVvTRW5ITVJ?
OS-RC-2 NX:0dVRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTlwMUGyOFMh|ryP MYrTRW5ITVJ?
NCI-SNU-16 NXPvPW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jkXGlEPTB;OT6yNVAzPiEQvF2= NEj2dJVUSU6JRWK=
SHP-77 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPnNGtlUUN3ME25MlcyPjZ{IN88US=> MnPzV2FPT0WU
A4-Fuk NYryXIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTlwN{W2NUDPxE1? MX3TRW5ITVJ?
NB6 NW\YOpJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHkTWM2OD17Lke2NFI6KM7:TR?= MnvsV2FPT0WU
JiyoyeP-2003 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPFTWM2OD1zMD60O|Q2KM7:TR?= NUHIVZNmW0GQR1XS
DMS-114 M4P2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDyd5pDUUN3ME2xNE42PDRzIN88US=> MlfxV2FPT0WU
NB7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWxNIlKSzVyPUGwMlc2OjZizszN NVrDPWtYW0GQR1XS
NCI-H747 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO2O2VWUUN3ME2xNU4yOjF4IN88US=> M2S1cHNCVkeHUh?=
HH M2LFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr1VoVtUUN3ME2xNU4{QDd4IN88US=> MVnTRW5ITVJ?
EW-18 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfsc3NKSzVyPUGxMlkxPDRizszN NIDYdlZUSU6JRWK=
CHP-126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD3T3lRUUN3ME2xNU46PzN6IN88US=> NV7RdlB{W0GQR1XS
NTERA-S-cl-D1 NF;4TnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kemhKSzVyPUGyMlAzPzhizszN M{G4dXNCVkeHUh?=
DEL NHO5eoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHewZYlKSzVyPUGyMlA6QDVizszN M2\lfXNCVkeHUh?=
LU-139 M4HocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT5XpdiUUN3ME2xNk42PDF|IN88US=> MkHXV2FPT0WU
P30-OHK MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LFc2lEPTB;MUKuOVQ4QSEQvF2= NVTmNld3W0GQR1XS
NCI-H1522 M3joRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7hOmhKSzVyPUGyMlc1PiEQvF2= M2DLcHNCVkeHUh?=
NCI-H1299 NIjxTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF|LkK5NVEh|ryP M1[1OHNCVkeHUh?=
UACC-257 NIjQSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfvRWZKSzVyPUGzMlUyOjZizszN MYXTRW5ITVJ?
Calu-6 NYrSR4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXkdo43UUN3ME2xN{43ODR4IN88US=> MVrTRW5ITVJ?
NCI-H1882 M1jLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LIdWlEPTB;MUOuPFU2PSEQvF2= NH3RfYdUSU6JRWK=
BB30-HNC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPP[o5CUUN3ME2xOE4xPjB7IN88US=> NF:1[VRUSU6JRWK=
ES1 NIPtV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXIXYhLUUN3ME2xOE4yPTVzIN88US=> M2ixU3NCVkeHUh?=
NCI-H1694 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;RellwUUN3ME2xOE41QDFzIN88US=> M2HHfHNCVkeHUh?=
IST-SL1 M13Ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfUZ2Z5UUN3ME2xOE46PjF4IN88US=> M1PnfHNCVkeHUh?=
ECC4 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknoTWM2OD1zNT6wOVU5KM7:TR?= NVzrfFc1W0GQR1XS
MDA-MB-134-VI NWPRU|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\RTWM2OD1zNT60NVMyKM7:TR?= MXfTRW5ITVJ?
SCH M2fQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF3LkS3Nlgh|ryP NV\FNGdYW0GQR1XS
SK-N-FI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojlTWM2OD1zNT62OVM1KM7:TR?= NITP[IRUSU6JRWK=
HDLM-2 M4rNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTaXVhKSzVyPUG2MlA4OTRizszN MUPTRW5ITVJ?
Ramos-2G6-4C10 NVzaeZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\I[Wc6UUN3ME2xOk4yOjl5IN88US=> NYLlcnhNW0GQR1XS
EW-24 NXfpd5FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLMUFZKSzVyPUG2MlE3PjFizszN MW\TRW5ITVJ?
NCI-H2141 NVG2Z3Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF4LkG4PUDPxE1? MXPTRW5ITVJ?
LC4-1 M3;ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T0TGlEPTB;MU[uOlEyQSEQvF2= MXHTRW5ITVJ?
HT-144 NV[0coZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyze4t{UUN3ME2xO{4xODZizszN MkWxV2FPT0WU
SK-MEL-1 NFTiVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jDcmlEPTB;MUeuNFA4OiEQvF2= NUnLWFhLW0GQR1XS
SCC-15 MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfNVmhKSzVyPUG3MlE3OzhizszN M2e3dHNCVkeHUh?=
C8166 NFPR[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF5Lk[4N|Mh|ryP Mlj2V2FPT0WU
GOTO Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnadVA4UUN3ME2xO{45OzR2IN88US=> NEXEb4pUSU6JRWK=
COR-L279 M1vRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\2TWM2OD1zOD6xN|YzKM7:TR?= NXrPOI1sW0GQR1XS
K-562 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fTdmlEPTB;MUiuO|E1OyEQvF2= M{nZSHNCVkeHUh?=
ES3 NEfNSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;6TWM2OD1zOD64NFQyKM7:TR?= M{TWSXNCVkeHUh?=
LU-165 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjVoJKSzVyPUG5MlcxODhizszN NF:xTopUSU6JRWK=
KM-H2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJyLkOxPFQh|ryP MnK2V2FPT0WU
RL NXPEV3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoTWM2OD1{MD65OlkzKM7:TR?= NFfsbXZUSU6JRWK=
EW-3 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiweWJKSzVyPUKxMlE5QDlizszN NELQeI9USU6JRWK=
A101D M3TQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXWS2pxUUN3ME2yNU4{PzV{IN88US=> MnfjV2FPT0WU
HUTU-80 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJzLkO5OFYh|ryP NEm3eXFUSU6JRWK=
NCI-H23 M3LDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfOXWRKSzVyPUKxMlM6QTJizszN MXjTRW5ITVJ?
PF-382 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJzLkS0NFMh|ryP MnXvV2FPT0WU
LB373-MEL-D MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXiR2JDUUN3ME2yNU42PjF3IN88US=> NH\wXGNUSU6JRWK=
TE-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17yd2lEPTB;MkGuOlM6PCEQvF2= Mme2V2FPT0WU
TE-9 NVfiZW82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvEd2FzUUN3ME2yNU45PTF|IN88US=> NIrzPZZUSU6JRWK=
Daudi NELaT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJzLkmzNFQh|ryP MVzTRW5ITVJ?
D-542MG Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHzTWM2OD1{Mj6wNlU3KM7:TR?= MVnTRW5ITVJ?
U-698-M M3vBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsfYJKSzVyPUKyMlQ3ODNizszN MYrTRW5ITVJ?
ES6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LzUmlEPTB;MkKuO|M3PiEQvF2= MoPvV2FPT0WU
DU-4475 NXjuWXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGzfVFKSzVyPUKzMlg5QTdizszN NGPkTIRUSU6JRWK=
ECC12 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjwOFNKSzVyPUK0MlI5ODNizszN NFmwPGpUSU6JRWK=
C2BBe1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfnTWM2OD1{ND6zNlM6KM7:TR?= NXLOc3BCW0GQR1XS
IST-SL2 NWL4SXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPScYRKSzVyPUK0MlQ{PjJizszN Mn\tV2FPT0WU
DJM-1 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P3U2lEPTB;MkSuOVIzOSEQvF2= MmnSV2FPT0WU
DMS-153 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzIZnhKSzVyPUK0Mlg3OTRizszN NVPLWYhZW0GQR1XS
NB13 NELHNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\LNJRKSzVyPUK1MlAzPjVizszN M1LG[nNCVkeHUh?=
SK-N-DZ M1HuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ4LkO0NVQh|ryP M4HYUHNCVkeHUh?=
COR-L88 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrDTWM2OD1{Nj61O|k3KM7:TR?= NIHBeXhUSU6JRWK=
LU-65 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\CXnFKSzVyPUK2Mlg2OzVizszN NFLX[|lUSU6JRWK=
TGBC1TKB NV\iPVNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnYXYlKSzVyPUK2Mlk5OjhizszN MVPTRW5ITVJ?
THP-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILadHRKSzVyPUK3MlIyPDFizszN NEnxcYpUSU6JRWK=
ONS-76 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fGPGlEPTB;MkeuN|MzKM7:TR?= M{Ls[HNCVkeHUh?=
LC-2-ad MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ5Lk[yN|Eh|ryP NFLkflhUSU6JRWK=
EW-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfwTWM2OD1{OT6xO|Q3KM7:TR?= MkP4V2FPT0WU
MS-1 NV;R[VZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LQRWlEPTB;M{CuO|I4QCEQvF2= NHH4TZdUSU6JRWK=
NCI-H2227 NITwb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzFUVdVUUN3ME2zNE46QDB4IN88US=> NEfmS29USU6JRWK=
LXF-289 M3jVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;OTWM2OD1|MT60OFkzKM7:TR?= MYfTRW5ITVJ?
MC116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3faW2lEPTB;M{KuNFgzPiEQvF2= MUXTRW5ITVJ?
EVSA-T MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPa[mZuUUN3ME2zNk4zPTh3IN88US=> MYTTRW5ITVJ?
CTB-1 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILsNFFKSzVyPUOzMlEyODFizszN M1LrN3NCVkeHUh?=
COLO-320-HSR NIDBXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInLfohKSzVyPUOzMlE3ODNizszN MVrTRW5ITVJ?
NCI-H2196 NGX6dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\oRWlEPTB;M{OuNlU2PyEQvF2= NEKzd5lUSU6JRWK=
LB2241-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rodmlEPTB;M{OuN|E{PSEQvF2= NGDld45USU6JRWK=
LS-513 M3\kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfRTWM2OD1|Mz64OlM5KM7:TR?= M4HiZXNCVkeHUh?=
LP-1 M3jZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KxTmlEPTB;M{OuPVk2PiEQvF2= M3n2OXNCVkeHUh?=
A253 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DIfWlEPTB;M{SuNlI6PiEQvF2= M4LjbXNCVkeHUh?=
SK-MM-2 NUHmdHN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLROopqUUN3ME2zOE46PDVzIN88US=> Mm\OV2FPT0WU
NCI-H1963 NF;Y[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN3LkOwO|Ih|ryP NVi4TYlEW0GQR1XS
MMAC-SF NWDMcnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTN3Lki3PFUh|ryP M4O2UHNCVkeHUh?=
LB831-BLC NUP5c25kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPPTWM2OD1|Nj6wOlU1KM7:TR?= M1zjTHNCVkeHUh?=
WSU-NHL NWHkNpA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN4LkG2OEDPxE1? MYjTRW5ITVJ?
CESS MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fLOmlEPTB;M{[uNlg1QCEQvF2= MXfTRW5ITVJ?
NEC8 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rxTGlEPTB;M{[uOVg{PSEQvF2= NHH2epVUSU6JRWK=
KNS-42 NYXrVFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnsTWM2OD1|Nz6xNlM4KM7:TR?= NGHkT49USU6JRWK=
MHH-CALL-2 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN5LkG4NlEh|ryP NFr1VVlUSU6JRWK=
K5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK4TWM2OD1|OD60N{DPxE1? NGP6WllUSU6JRWK=
CP66-MEL MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm4N4xDUUN3ME2zPU4xPzN|IN88US=> NGL1SHdUSU6JRWK=
OPM-2 M4T1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXvUIJ[UUN3ME2zPU45PDN{IN88US=> NX23eVNYW0GQR1XS
IST-MES1 M4G4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;nUWlEPTB;NECuN|A6PiEQvF2= MVrTRW5ITVJ?
EC-GI-10 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfoR25oUUN3ME20NU42QDB3IN88US=> NVvYVJRWW0GQR1XS
CTV-1 NUjTUVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmxeG1KSzVyPUSyMlg1ODZizszN MlLlV2FPT0WU
DG-75 NV3NcGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3zd3lKSzVyPUSzMlc2QTVizszN NVf0fFlEW0GQR1XS
KNS-81-FD MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LNSGlEPTB;NEWuOFA2QCEQvF2= MmHaV2FPT0WU
NCI-H82 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX71bGI3UUN3ME20OU42PzV6IN88US=> M3;O[XNCVkeHUh?=
RPMI-8866 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LMc2lEPTB;NE[uNVg4OyEQvF2= M{DD[nNCVkeHUh?=
ACN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrWc2NKSzVyPUS2MlQ{PCEQvF2= NYXZbWN7W0GQR1XS
NCI-H1395 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i3cGlEPTB;NE[uOFc2PiEQvF2= NEXZTINUSU6JRWK=
NCI-H209 NEHDXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGwXFY6UUN3ME20O{4yPDB3IN88US=> MYTTRW5ITVJ?
TGW MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL2WpVoUUN3ME20PU4xPzlzIN88US=> MVzTRW5ITVJ?
NCI-H748 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;iTWM2OD12OT60O|U{KM7:TR?= NVyzfJlxW0GQR1XS
EKVX M{PVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ETWM2OD12OT62OlI5KM7:TR?= NXfHZ4dPW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 400+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Not yet recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. August 15 2019 Phase 2
NCT03958669 Not yet recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research July 1 2019 --
NCT03764293 Not yet recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. January 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID